Latest From Grail Inc.
GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.
In a busy week, Carrick Therapeutics has added to its oncology pipeline, as well as bringing in Celgene deal maker George Golumbeski.
Appointments: Senior Hires At Allergan, Novartis, Array Biopharma, Zelluna Immunotherapy, Grail, Alzheon And Sigilon Therapeutics
Pfizer Oncology has lost its CMO to Allergan, while Novartis beefs up its ethical leadership, Array Biopharma appoints a new chair and Sigilon raids Bioverativ for its new CEO.
The worldwide liquid biopsy market is expected to reach $2.0bn by 2022, according to a new report by Meddevicetracker, "Oncology: Liquid Biopsy Products." The growth is driven by the rising global incidence of cancers, which, in turn, fuels innovation among companies to develop noninvasive diagnostic assays that obviate the need for tissue biopsy. This is the first in a two-part series providing an overview of the liquid biopsy market, as well as the technologies developed by the larger players in this space, and examining the biggest barriers and growth drivers. In the second part, we'll take a closer look at emerging companies in the sector and offer key insights from C-level attendees at the recent Liquid Biopsy Conference in San Francisco.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Grail Bio
- North America
- Company Type
- Parent & Subsidiaries
- Grail Inc.
- Senior Management
Hans Bishop, CEO
Matthew Young, COO & CFO
George Golumbeski, PhD, Pres.
Alex Aravanis, MD, PhD, CSO
Onaisz Cadoret-Manier, Chief Commercial Officer
Angela Lai, CTO
- Contact Info
Phone: (650) 542-0372
1525 O'Brien Dr.
Menlo Park, CA 94025
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.